A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Status:
Recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
This study aims to find the appropriately safe and effective dose and dosing frequency for
eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further
clinical development. The study will last approximately 62 weeks and may include up to 31
visits.